Tilray Brands (NASDAQ:TLRY) is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.
Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products. The company has expanded into adjacent consumer categories via strategic acquisitions, integrating brands in hemp foods, craft beverages and pet wellness. This diversified approach supports Tilray Brands’ goal of serving both medical and adult-use markets while extending its reach into broader lifestyle and health-and-wellness segments.
Founded in 2013, Tilray became the first global cannabis company to list on a major U.S. exchange in 2018. In 2021, it completed a transformative merger with Aphria, creating one of the world’s largest cannabis companies by production capacity. Headquartered in New York with integrated operations in Canada, the United States, Europe, Australia, Latin America and the Caribbean, Tilray Brands leverages international scale to access regulated markets and support global research collaborations.
Tilray Brands is led by a management team with deep experience in consumer packaged goods, pharmaceuticals and regulated industries. The company’s executive leadership emphasizes product innovation, regulatory compliance and operational excellence, positioning Tilray Brands to pursue growth opportunities across its core cannabis business and complementary consumer lifestyle categories.
